In the Claims

Please make the following amendments to the claims, without prejudice to the filing of future continuing applications.

- 1. 3. (Cancel)
- 4. (AMENDED) A monoclonal antibody specifically reacting with a peptide having an amino acid sequence of residues 12 to 24 of SEQ ID NO: 2.
- 5. (AMENDED) # The monoclonal antibody as claimed in Claim 4 which is a mouse IgG.
 - 6. (CANCEL)
- 7. (AMENDED) A method of assaying the 19P2 ligand or a derivative thereof in a test fluid which comprises using the monoclonal antibody as claimed in Claim 1 or of Claim 4 in an assay, said assay comprising contacting a test fluid sample to be assayed with said monoclonal antibody and detecting ligand in said sample.
 - 8. (Cancel)
- 9. (AMENDED) A hybridoma cell producing the monoclonal antibody as claimed in Claim 1 or of Claim 4.
- 10. (Amended) # **The** monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 11.
- 11. (AMENDED) A method for detecting 19P2 ligand in a sample, comprising **contacting** assaying said sample with a

monoclonal antibody of claim 10 and detecting such **ligand**

- 12. 13. (Cancel)
- 14. (AMENDED) A method for detecting 19P2 ligand in a sample, comprising assaying contacting said sample with a monoclonal antibody of claim 10 and an antibody which specifically binds to a peptide having the amino acid sequence of SEQ ID NO: 7, and detecting such ligand binding.
 - 15. 17. (Cancel)
- 18. (AMENDED) # The monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:12.
- 19. (AMENDED) A The monoclonal antibody of claim 4, which specifically binds with a peptide having the amino acid sequence of amino acid residues 12 to 24 of SEQ ID NO: 1, amino acid residues 12 to 24 of SEQ ID NO: 2, or amino acid residues 12 to 24 of SEQ ID NO: 3.
- 20. (AMENDED) # The monoclonal antibody of claim 4, which specifically binds with a 19P2 ligand peptide, but which does not bind with a peptide having the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 6.
- 21. (AMENDED) \triangleq **The** monoclonal antibody of claim 4, which is P2L-1Ta.
 - 22. 24. (Cancel)

- 25. (AMENDED) An isolated hybridoma cell line, said cell line producing the antibody P2L-1Ta, P2L-3Ta, P2L-1Ca or P2L-2Ca.
- 26. (AMENDED) ♣ **The** method of claim ♣ **11** for detecting 19P2 ligand in a sample, comprising assaying said sample wherein said 19P2 ligand is attached to a carrier.
- 27. (AMENDED) \triangleq **The** method of claim $\stackrel{45}{=}$ **11** wherein $\stackrel{a}{=}$ **said** monoclonal antibody is attached to a carrier.
- 28. (AMENDED) $\stackrel{\blacktriangle}{=}$ The method of claim $\stackrel{45}{=}$ 11 wherein $\stackrel{\clubsuit}{=}$ said monoclonal antibody is attached to a detectable signal or label.
- 29. (AMENDED) A **The** method of claim 45 11 which is a sandwich assay.
- 30. (AMENDED) \triangleq **The** method of claim $\stackrel{15}{=}$ 11 which is a competitive inhibition assay.
- 31. (AMENDED) Alpha method of claim Alpha in which one monoclonal antibody is P2L-1Ta, P2L-3Ta, P2L-1Ca or P2L-2Ca.